FDA clearance for an IND application is a critical regulatory milestone for biotech companies, often leading to positive investor sentiment. This clearance allows VYNE to proceed with clinical trials, which is a step closer to bringing a new product to market. Given the importance of product pipelines in the biotech industry, this news is likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.